Business
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
(via TheNewswire) Kelowna, British Columbia – May 19, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"(via TheNewswire) Kelowna, British Columbia – May 19, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an independent review board, for Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo Nordisk’s® commercially available Wegovy® tablets (the “Study”). “Lexaria is delighted to have received the independent ethics review board approval so quickly,” said Richard Christopher, CEO of Lexaria Bioscience. “Lexaria is looking for this Study to provide the positive outcomes necessary to support commercial collaboration within the pharmaceutical industry related to Lexaria’s demonstrated improvements in delivering oral GLP-1 drugs in real-world environments.” Lexaria is seeking to preserve the superior safety and tolerability profiles evidenced in its previous glucagon-like peptide-1 (“GLP-1”) studies such as Human Study #4 (GLP-1-H25-4), combined with pharmacokinetic (“PK”) performance that matches or exceeds the Wegovy® tablet control over a 5-week period. Previous Lexaria salcaprozate sodium (“SNAC”)-inclusive DHT-sema single dose studies such as Human Pilot Studies #1 and #2 (GLP-1-H24-1 and GLP-1-H24-2) evidenced PK performance that matched or exceeded the Rybelsus® control arm and also evidenced noteworthy safety and tolerability profiles. The results of this Study are expected to be carefully reviewed by the pharmaceutical industry in order to evaluate the possibility of entering into commercial relationships focused on Lexaria’s proprietary DehydraTECH technology. Laboratory tablet composition work and commercial-scale manufacturing for the DHT-sema test articles for the Study have been performed. Third-party independent lab quality-control (“QC”) testing of those test articles is currently underway and is expected to be complete in early June. Packaging of all the test articles suitable for the Study will be undertaken in parallel with this. The design of the Study is now complete: a five-week parallel group design, investigating three separate arms to assess safety & tolerability and PK properties that will compare SNAC-inclusive DHT-sema tablet ...